| Cell line |
Species |
Tissue |
Culture medium |
Cencentration |
|
293
|
human |
kidney; fetal |
Dulbecco's modified Eagle's medium |
100 (μg/ml)
|
|
293
|
human |
kidney; fetal |
Dulbecco's modified Eagle's medium |
400 (μg/ml)
|
|
HMC1
|
human |
|
Dulbecco's modified Eagle's medium |
200 (μg/ml)
|
|
293
|
human |
kidney; fetal |
Dulbecco's modified Eagle's medium |
1 (μg/ml)
|
|
293
|
human |
kidney; fetal |
Dulbecco's modified Eagle's medium |
1 (μg/ml)
|
|
293
|
human |
kidney; fetal |
Dulbecco's modified Eagle's medium |
350 (μg/ml)
|
|
MDA-MB-435
|
human |
breast |
Dulbecco's modified Eagle's medium |
200 (μg/ml)
|
|
A9
|
mouse/mouse |
hybridoma |
Dulbecco's modified Eagle's medium |
200 (μg/ml)
|
|
MCF7
|
human |
pleural effusion (metastasis); adenocarcinoma (mammary gland primary) |
Dulbecco's modified Eagle's medium |
800 (μg/ml)
|
|
FO1-12
|
|
|
Dulbecco's modified Eagle's medium |
500 (μg/ml)
|
|
COS-7
|
monkey, African green |
kidney |
Dulbecco's modified Eagle's medium |
100 (μg/ml)
|
|
3T3-L1
|
mouse |
embryo |
Dulbecco's modified Eagle's medium |
500 (μg/ml)
|
|
HLE
|
human |
|
Dulbecco's modified Eagle's medium |
300 (μg/ml)
|
|
MDA-MB-231
|
human |
pleural effusion (metastasis); adenocarcinoma (mammary gland primary) |
Dulbecco's modified Eagle's medium |
400 (μg/ml)
|
|
C2C12
|
mouse |
muscle |
Dulbecco's modified Eagle's medium |
300 (μg/ml)
|
|
MCF7
|
human |
pleural effusion (metastasis); adenocarcinoma (mammary gland primary) |
Dulbecco's modified Eagle's medium |
200 (μg/ml)
|
|
293
|
human |
kidney; fetal |
Dulbecco's modified Eagle's medium |
500 (μg/ml)
|
|
BJAB
|
|
|
RPMI 1640 Medium |
300 (μg/ml)
|
|
PC-3
|
human |
bone (metastasis); adenocarcinoma (prostate primary) |
Dulbecco's modified Eagle's medium |
400 (μg/ml)
|
|
LNCaP
|
human |
prostatic adenocarcinoma |
Dulbecco's modified Eagle's medium |
400 (μg/ml)
|
|
SCC-13
|
|
|
Dulbecco's modified Eagle's medium |
500 (μg/ml)
|
|
CHO-K1
|
hamster, Chinese |
ovary |
|
600 (μg/ml)
|
|
A-431
|
human |
epidermis; epidermoid carcinoma |
Dulbecco's modified Eagle's medium |
750 (μg/ml)
|
|
NIH:OVCAR-3
|
human |
ascites (metastasis); adenocarcinoma (ovary primary) |
RPMI 1640 Medium |
250 (μg/ml)
|
|
LNCaP
|
human |
prostatic adenocarcinoma |
Dulbecco's modified Eagle's medium |
250 (μg/ml)
|
|
CHO-K1
|
hamster, Chinese |
ovary |
Dulbecco's modified Eagle's medium |
300 (μg/ml)
|
|
CHO-K1
|
hamster, Chinese |
ovary |
Eagle's minimal essential medium |
350 (μg/ml)
|
|
A-431
|
human |
epidermis; epidermoid carcinoma |
Dulbecco's modified Eagle's medium |
100 (μg/ml)
|
|
Hep G2
|
human |
liver; hepatocellular carcinoma |
Minimal essential medium |
500 (μg/ml)
|
|
CHO-K1
|
hamster, Chinese |
ovary |
Dulbecco's modified Eagle's medium |
200 (μg/ml)
|
|
GH3
|
rat |
pituitary tumor |
Dulbecco's modified Eagle's medium |
250 (μg/ml)
|
|
GH3
|
rat |
pituitary tumor |
DMEM + F12 medium |
400 (μg/ml)
|
|
Hep G2
|
human |
liver; hepatocellular carcinoma |
Dulbecco's modified Eagle's medium |
400 (μg/ml)
|
|
293
|
human |
kidney; fetal |
RPMI 1640 Medium |
800 (μg/ml)
|
|
U-2 OS
|
human |
bone; osteosarcoma |
|
100 (μg/ml)
|
|
293T
|
human |
Kidney (embryonic) |
Dulbecco's modified Eagle's medium |
500 (μg/ml)
|
|
HeLa
|
human |
cervix; adenocarcinoma |
Dulbecco's modified Eagle's medium |
200 (μg/ml)
|
|
143B
|
human |
bone; osteosarcoma |
|
500 (μg/ml)
|
|
P116
|
human |
T lymphocyte; ZAP-70 negative; model for T cell receptor signaling |
|
100 (μg/ml)
|
|
HL-60
|
human |
peripheral blood; promyeloblast; acute promyelocytic leukemia |
RPMI 1640 Medium |
100 (μg/ml)
|
|
293
|
human |
kidney; fetal |
Dulbecco's modified Eagle's medium |
200 (μg/ml)
|
|
HEK
|
|
|
Dulbecco's modified Eagle's medium |
300 (μg/ml)
|
|
CV-1
|
monkey, African green |
kidney |
Eagle's minimal essential medium |
25 (μg/ml)
|
|
293T
|
human |
Kidney (embryonic) |
Dulbecco's modified Eagle's medium |
500 (μg/ml)
|
|
HeLa
|
human |
cervix; adenocarcinoma |
Dulbecco's modified Eagle's medium |
400 (μg/ml)
|
|
NCI-H526
|
human |
bone marrow (metastasis); carcinoma; classic small cell lung cancer (lung primary) |
|
400 (μg/ml)
|
|
NIH/3T3
|
mouse |
embryo |
|
250 (μg/ml)
|
|
RBL-1
|
rat |
peripheral blood; basophil; leukemia |
|
200 (μg/ml)
|
|
COS-1
|
monkey, African green |
kidney |
DMEM / F 12 medium |
800 (μg/ml)
|
|
NIH/3T3
|
mouse |
embryo |
Dulbecco's modified Eagle's medium |
100 (μg/ml)
|
|
MCF 10A
|
human |
mammary gland; fibrocystic disease |
DMEM / F 12 medium |
200 (μg/ml)
|
|
293
|
human |
kidney; fetal |
Dulbecco's modified Eagle's medium |
50 (μg/ml)
|
|
293
|
human |
kidney; fetal |
Dulbecco's modified Eagle's medium |
50 (μg/ml)
|
|
MCF7
|
human |
pleural effusion (metastasis); adenocarcinoma (mammary gland primary) |
Dulbecco's modified Eagle's medium |
750 (μg/ml)
|
|
Huh-7
|
|
|
Dulbecco's modified Eagle's medium |
350 (μg/ml)
|
|
1259MEL
|
|
|
RPMI 1640 Medium |
50 (μg/ml)
|
|
CRC
|
|
|
|
1 (μg/ml)
|
|
BG01
|
|
|
Dulbecco's modified Eagle's medium |
100 (μg/ml)
|
|
L1.2
|
|
|
RPMI 1640 Medium |
700 (μg/ml)
|
|
HCT 116
|
human |
colon; colorectal carcinoma |
|
600 (μg/ml)
|
|
CT-26
|
|
|
Dulbecco's modified Eagle's medium |
700 (μg/ml)
|
|
11D6
|
|
|
|
300 (μg/ml)
|
|
293/EBNA-1
|
|
|
Dulbecco's modified Eagle's medium |
300 (μg/ml)
|
|
αTC1-6
|
|
|
Dulbecco's modified Eagle's medium |
200 (μg/ml)
|
|
P3-X63-Ag8.653
|
|
|
RPMI 1640 Medium |
250 (μg/ml)
|
